Form 8-K - Current report:
SEC Accession No. 0001193125-23-173796
Filing Date
2023-06-23
Accepted
2023-06-23 16:03:29
Documents
71
Period of Report
2023-06-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d514661d8k.htm   iXBRL 8-K 132138
2 EX-23.1 d514661dex231.htm EX-23.1 2038
3 EX-99.1 d514661dex991.htm   iXBRL EX-99.1 834364
4 EX-99.2 d514661dex992.htm EX-99.2 150865
  Complete submission text file 0001193125-23-173796.txt   6144963

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA elvn-20230623.xsd EX-101.SCH 48871
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE elvn-20230623_cal.xml EX-101.CAL 36382
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE elvn-20230623_def.xml EX-101.DEF 206753
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20230623_lab.xml EX-101.LAB 409730
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20230623_pre.xml EX-101.PRE 319947
65 EXTRACTED XBRL INSTANCE DOCUMENT d514661d8k_htm.xml XML 1098242
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 231037629
SIC: 2834 Pharmaceutical Preparations